RB1 and pachyonychia congenita: However, co-administration of 666-15 abolished JQ1 resistance of RB-deficient PC-3 tumors (Fig. 6e–g), suggesting that there was seemingly no obvious drug-drug interaction between these two compounds under these conditions.